Brian E Lally

Summary

Affiliation: Fox Chase Cancer Center
Country: USA

Publications

  1. ncbi Trends in the outcomes for patients with limited stage small cell lung cancer: An analysis of the Surveillance, Epidemiology, and End Results database
    Brian E Lally
    Wake Forest University Health Sciences, Department of Radiation Oncology, Medical Center Boulevard, Winston Salem, NC 27157, United States
    Lung Cancer 64:226-31. 2009
  2. ncbi Small cell lung cancer: have we made any progress over the last 25 years?
    Brian E Lally
    Department of Radiation Oncology, Wake Forest University Health Sciences, Winston Salem, North Carolina, USA
    Oncologist 12:1096-104. 2007
  3. ncbi The risk of death from heart disease in patients with nonsmall cell lung cancer who receive postoperative radiotherapy: analysis of the Surveillance, Epidemiology, and End Results database
    Brian E Lally
    Department of Radiation Oncology, Wake Forest University Health Sciences, Winston Salem, NC 27157 1030, USA
    Cancer 110:911-7. 2007
  4. ncbi Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database
    Brian E Lally
    Department of Radiation Oncology, Wake Forest University School of Medicine, Medical Center Blvd, Winston Salem, NC 27157 1030, USA
    J Clin Oncol 24:2998-3006. 2006
  5. ncbi Identification and biological evaluation of a novel and potent small molecule radiation sensitizer via an unbiased screen of a chemical library
    Brian E Lally
    Department of Radiation Oncology, Wake Forest University Health Sciences, Winston Salem, North Carolina, USA
    Cancer Res 67:8791-9. 2007

Detail Information

Publications5

  1. ncbi Trends in the outcomes for patients with limited stage small cell lung cancer: An analysis of the Surveillance, Epidemiology, and End Results database
    Brian E Lally
    Wake Forest University Health Sciences, Department of Radiation Oncology, Medical Center Boulevard, Winston Salem, NC 27157, United States
    Lung Cancer 64:226-31. 2009
    ..In order to continue to improve clinical outcomes, clinical trials investigating new treatment paradigms are needed...
  2. ncbi Small cell lung cancer: have we made any progress over the last 25 years?
    Brian E Lally
    Department of Radiation Oncology, Wake Forest University Health Sciences, Winston Salem, North Carolina, USA
    Oncologist 12:1096-104. 2007
    ..It is imperative that, whenever possible, patients be given the opportunity to participate in future clinical trials so that the survival for these patients can continue to improve...
  3. ncbi The risk of death from heart disease in patients with nonsmall cell lung cancer who receive postoperative radiotherapy: analysis of the Surveillance, Epidemiology, and End Results database
    Brian E Lally
    Department of Radiation Oncology, Wake Forest University Health Sciences, Winston Salem, NC 27157 1030, USA
    Cancer 110:911-7. 2007
    ..This study was designed to investigate whether the mortality from heart disease, a manifestation of intercurrent disease after postoperative radiotherapy (PORT), has decreased over time for patients with nonsmall cell lung cancer (NSCLC)...
  4. ncbi Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database
    Brian E Lally
    Department of Radiation Oncology, Wake Forest University School of Medicine, Medical Center Blvd, Winston Salem, NC 27157 1030, USA
    J Clin Oncol 24:2998-3006. 2006
    ..To investigate the association between survival and postoperative radiotherapy (PORT) in patients with resected non-small-cell lung cancer (NSCLC)...
  5. ncbi Identification and biological evaluation of a novel and potent small molecule radiation sensitizer via an unbiased screen of a chemical library
    Brian E Lally
    Department of Radiation Oncology, Wake Forest University Health Sciences, Winston Salem, North Carolina, USA
    Cancer Res 67:8791-9. 2007
    ..These results show the potential of this cell-based, high-throughput screening method to identify novel radiosensitizers and suggest that NS-123 and similar nitrophenol compounds may be effective in antiglioma modalities...